Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease

References

• Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol. 2022 Mar 3;15(1):20.
   PubMed Web of Science ®Google Scholar
• Leonard A, Tisdale JF, Krishnamurti L, et al. Hematopoietic stem cell transplantation in sickle cell disease. In: Gladwin M, Kato G, and Novelli E, editors. Sickle cell disease. New Yark (NY): McGraw-Hill Education. 2021;492–527.
   Google Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018 Mar 15;4(1):18010. doi: 10.1038/nrdp.2018.10
   PubMedGoogle Scholar
• Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Front Physiol. 2020;11:435. doi: 10.3389/fphys.2020.00435
   PubMed Web of Science ®Google Scholar
• Leonard A, Tisdale JF. Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced. Expert Rev Hematol. 2018 Jul;11(7):547–565. doi: 10.1080/17474086.2018.1486703
   PubMed Web of Science ®Google Scholar
• Bernaudin F, Dalle JH, Bories D, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica. 2020 Jan;105(1):91–101. doi: 10.3324/haematol.2018.213207
   PubMed Web of Science ®Google Scholar
• Rotin LE, Viswabandya A, Kumar R, et al. A systematic review comparing allogeneic hematopoietic stem cell transplant to gene therapy in sickle cell disease. Hematology. 2023 Dec;28(1):2163357. doi: 10.1080/16078454.2022.2163357
   PubMed Web of Science ®Google Scholar
• Howard J. Sickle cell disease: when and how to transfuse. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):625–631.
   PubMedGoogle Scholar
• Leonard A, Bertaina A, Bonfim C, et al. Curative therapy for hemoglobinopathies: an international Society for cell & gene therapy stem cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2022 Mar;24(3):249–261. doi: 10.1016/j.jcyt.2021.09.003
   PubMed Web of Science ®Google Scholar
• Krishnamurti L. Hematopoietic cell transplantation for sickle cell disease. Front Pediatr. 2020;8:551170. doi: 10.3389/fped.2020.551170
   PubMed Web of Science ®Google Scholar
• Kassim AA, Sharma D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):259–266. doi: 10.1016/j.hemonc.2017.05.008
   PubMedGoogle Scholar
• Magrin E, Semeraro M, Hebert N, et al. Long-term outcomes of lentiviral gene therapy for the beta-hemoglobinopathies: the HGB-205 trial. Nat Med. 2022 Jan;28(1):81–88. doi: 10.1038/s41591-021-01650-w
   PubMed Web of Science ®Google Scholar
• Eapen M, Brazauskas R, Walters MC, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019 Nov;6(11):e585–e596. doi: 10.1016/S2352-3026(19)30154-1
   PubMed Web of Science ®Google Scholar
• Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017 Mar 16;129(11):1548–1556. doi: 10.1182/blood-2016-10-745711
   PubMed Web of Science ®Google Scholar
• Jang T, Mo G, Stewart C, et al. Hematopoietic stem cell transplant for sickle cell disease: PATIENT SELEction and timing based on sickle cell-related multiple chronic Conditions. Cell Transplant. 2021 Jan;30:9636897211046559.
   Web of Science ®Google Scholar
• Quinn CT. Sickle cell disease in childhood: from newborn screening through transition to adult medical care. Pediatr Clin North Am. 2013 Dec;60(6):1363–1381. doi: 10.1016/j.pcl.2013.09.006
   PubMed Web of Science ®Google Scholar
• Tanhehco YC, Bhatia M. Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now? Curr Opin Hematol. 2019 Nov;26(6):448–452. doi: 10.1097/MOH.0000000000000541
   PubMed Web of Science ®Google Scholar
• Guilcher GMT, Truong TH, Saraf SL, et al. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. Semin Hematol. 2018 Apr;55(2):87–93. doi: 10.1053/j.seminhematol.2018.04.011
   PubMed Web of Science ®Google Scholar
• Abraham AA, Tisdale JF. Gene therapy for sickle cell disease: moving from the bench to the bedside. Blood. 2021 Sep 16;138(11):932–941.
   PubMed Web of Science ®Google Scholar
• Bhalla N, Bhargav A, Yadav SK, et al. Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: a review. Front Med. 2023;10:1036939. doi: 10.3389/fmed.2023.1036939
   Web of Science ®Google Scholar
• Shenoy S. Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions. Ther Adv Hematol. 2013 Oct;4(5):335–344. doi: 10.1177/2040620713483063
   PubMedGoogle Scholar
• Limerick E, Abraham A. Across the myeloablative spectrum: hematopoietic cell transplant conditioning regimens for pediatric patients with sickle cell disease. J Clin Med. 2022 Jul 3;11(13):3856. doi: 10.3390/jcm11133856
   PubMed Web of Science ®Google Scholar
• Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007 Oct 1;110(7):2749–2756. doi: 10.1182/blood-2007-03-079665
   PubMed Web of Science ®Google Scholar
• Brazauskas R, Scigliuolo GM, Wang HL, et al. Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. Blood. 2020 Jul 30;136(5):623–626. doi: 10.1182/blood.2020005687
   PubMed Web of Science ®Google Scholar
• Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998 Jul;22(1):1–6. doi: 10.1038/sj.bmt.1701291
   PubMed Web of Science ®Google Scholar
• Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000 Mar 15;95(6):1918–1924.
   PubMed Web of Science ®Google Scholar
• Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7(12):665–673. doi: 10.1053/bbmt.2001.v7.pm11787529
   PubMed Web of Science ®Google Scholar
• Walters MC, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010 Feb;16(2):263–272. doi: 10.1016/j.bbmt.2009.10.005
   PubMed Web of Science ®Google Scholar
• Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the center for international Blood and transplant Research. Br J Haematol. 2007 Jun;137(5):479–485. doi: 10.1111/j.1365-2141.2007.06592.x
   PubMed Web of Science ®Google Scholar
• Majumdar S, Robertson Z, Robinson A, et al. Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center’s experience. Bone Marrow Transplant. 2010 May;45(5):895–900. doi: 10.1038/bmt.2009.244
   PubMed Web of Science ®Google Scholar
• McPherson ME, Hutcherson D, Olson E, et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant. 2011 Jan;46(1):27–33. doi: 10.1038/bmt.2010.60
   PubMed Web of Science ®Google Scholar
• Dallas MH, Triplett B, Shook DR, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013 May;19(5):820–830. doi: 10.1016/j.bbmt.2013.02.010
   PubMed Web of Science ®Google Scholar
• Dedeken L, Le PQ, Azzi N, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients. Br J Haematol. 2014 May;165(3):402–408. doi: 10.1111/bjh.12737
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Isgro A, Sodani P, et al. Hematopoietic SCT for the black African and non-black African variants of sickle cell anemia. Bone Marrow Transplant. 2014 Nov;49(11):1376–1381. doi: 10.1038/bmt.2014.167
   PubMed Web of Science ®Google Scholar
• Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014 Jul;49(7):913–920. doi: 10.1038/bmt.2014.84
   PubMed Web of Science ®Google Scholar
• Strocchio L, Zecca M, Comoli P, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br J Haematol. 2015 Jun;169(5):726–736. doi: 10.1111/bjh.13352
   PubMed Web of Science ®Google Scholar
• Marzollo A, Calore E, Tumino M, et al. Treosulfan-based conditioning regimen in sibling and alternative donor hematopoietic stem cell transplantation for children with sickle cell disease. Mediterr J Hematol Infect Dis. 2017;9(1):e2017014. doi: 10.4084/mjhid.2017.014
   PubMedGoogle Scholar
• John TD, Friend B, Yassine K, et al. Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas children’s Hospital experience. Bone Marrow Transplant. 2021 Nov;56(11):2797–2803. doi: 10.1038/s41409-021-01415-6
   PubMed Web of Science ®Google Scholar
• Foell J, Kleinschmidt K, Jakob M, et al. Alternative donor: alphass/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease. Hematol Oncol Stem Cell Ther. 2020 Jun;13(2):98–105. doi: 10.1016/j.hemonc.2019.12.006
   PubMedGoogle Scholar
• Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003 Aug;9(8):519–528. doi: 10.1016/S1083-8791(03)00192-7
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Duerst R, Tse W, et al. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet. 2004 Jul 10-16;364(9429):156–162. doi: 10.1016/S0140-6736(04)16628-2
   PubMed Web of Science ®Google Scholar
• Horan JT, Liesveld JL, Fenton P, et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant. 2005 Jan;35(2):171–177. doi: 10.1038/sj.bmt.1704745
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Spasojevic I, Morris A, et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. Biol Blood Marrow Transplant. 2007 Dec;13(12):1422–1426. doi: 10.1016/j.bbmt.2007.08.050
   PubMed Web of Science ®Google Scholar
• Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008 Nov;14(11):1270–1278. doi: 10.1016/j.bbmt.2008.08.016
   PubMed Web of Science ®Google Scholar
• Matthes-Martin S, Lawitschka A, Fritsch G, et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol. 2013 Apr;90(4):308–312. doi: 10.1111/ejh.12082
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014 Jul 2;312(1):48–56. doi: 10.1001/jama.2014.7192
   PubMed Web of Science ®Google Scholar
• King AA, Kamani N, Bunin N, et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015 Dec;90(12):1093–1098. doi: 10.1002/ajh.24183
   PubMed Web of Science ®Google Scholar
• Krishnamurti L, Neuberg DS, Sullivan KM, et al. Bone marrow transplantation for adolescents and young adults with sickle cell disease: results of a prospective multicenter pilot study. Am J Hematol. 2019 Apr;94(4):446–454. doi: 10.1002/ajh.25401
   PubMed Web of Science ®Google Scholar
• Guilcher GMT, Monagel DA, Nettel-Aguirre A, et al. Nonmyeloablative matched sibling donor hematopoietic cell transplantation in children and adolescents with sickle cell disease. Biol Blood Marrow Transplant. 2019 Jun;25(6):1179–1186. doi: 10.1016/j.bbmt.2019.02.011
   PubMed Web of Science ®Google Scholar
• Alzahrani M, Damlaj M, Jeffries N, et al. Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. Br J Haematol. 2021 Feb;192(4):761–768. doi: 10.1111/bjh.17311
   PubMed Web of Science ®Google Scholar
• Gilman AL, Eckrich MJ, Epstein S, et al. Alternative donor hematopoietic stem cell transplantation for sickle cell disease. Blood Adv. 2017 Jul 11;1(16):1215–1223. doi: 10.1182/bloodadvances.2017005462
   PubMed Web of Science ®Google Scholar
• Foell J, Pfirstinger B, Rehe K, et al. Haploidentical stem cell transplantation with CD3(+)-/CD19(+)- depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study. Bone Marrow Transplant. 2017 Jun;52(6):938–940. doi: 10.1038/bmt.2017.49
   PubMed Web of Science ®Google Scholar
• Kurzay M, Hauck F, Schmid I, et al. T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors. Haematologica. 2019 Oct;104(10):e478–e482. doi: 10.3324/haematol.2018.215285
   PubMed Web of Science ®Google Scholar
• Cairo MS, Talano JA, Moore TB, et al. Familial Haploidentical stem cell transplant in children and adolescents with high-risk sickle cell disease: a phase 2 clinical trial. JAMA Pediatr. 2020 Feb 1;174(2):195–197. doi: 10.1001/jamapediatrics.2019.4715
   PubMed Web of Science ®Google Scholar
• Jaiswal SR, Bhakuni P, Aiyer HM, et al. CTLA4Ig in an extended schedule along with sirolimus improves outcome with a distinct pattern of immune reconstitution following post-transplantation cyclophosphamide-based Haploidentical transplantation for hemoglobinopathies. Biol Blood Marrow Transplant. 2020 Aug;26(8):1469–1476. doi: 10.1016/j.bbmt.2020.05.005
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22;120(22):4285–4291. doi: 10.1182/blood-2012-07-438408
   PubMed Web of Science ®Google Scholar
• Fitzhugh CD, Hsieh MM, Taylor T, et al. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv. 2017 Apr 25;1(11):652–661. doi: 10.1182/bloodadvances.2016002972
   PubMed Web of Science ®Google Scholar
• Saraf SL, Oh AL, Patel PR, et al. Haploidentical peripheral Blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease. Biol Blood Marrow Transplant. 2018 Aug;24(8):1759–1765. doi: 10.1016/j.bbmt.2018.03.031
   PubMed Web of Science ®Google Scholar
• de la Fuente J, Dhedin N, Koyama T, et al. Haploidentical bone Marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative. Biol Blood Marrow Transplant. 2019 Jun;25(6):1197–1209. doi: 10.1016/j.bbmt.2018.11.027
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Cooke KR, Gamper CJ, et al. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematol. 2019 Apr;6(4):e183–e193. doi: 10.1016/S2352-3026(19)30031-6
   PubMed Web of Science ®Google Scholar
• Mallhi KK, Srikanthan MA, Baker KK, et al. HLA-Haploidentical hematopoietic cell transplantation for treatment of nonmalignant diseases using Nonmyeloablative conditioning and post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2020 Jul;26(7):1332–1341. doi: 10.1016/j.bbmt.2020.03.018
   PubMed Web of Science ®Google Scholar
• Kharya G, Bakane A, Agarwal S, et al. Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease. Bone Marrow Transplant. 2021 Feb;56(2):492–504. doi: 10.1038/s41409-020-01054-3
   PubMed Web of Science ®Google Scholar
• Abdel-Azim H, Mahadeo KM, Zhao Q, et al. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: an alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. Am J Hematol. 2015;90(11):1021–1026. doi: 10.1002/ajh.24141
   PubMed Web of Science ®Google Scholar
• Shenoy S, Eapen M, Panepinto JA, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016 Nov 24;128(21):2561–2567. doi: 10.1182/blood-2016-05-715870
   PubMed Web of Science ®Google Scholar
• Aydin M, Dovern E, Leeflang MMG, et al. Haploidentical allogeneic stem cell transplantation in sickle cell disease: a systematic review and meta-Analysis. Transplant Cell Ther. 2021 Dec;27(12):e1004 1–e1004 8. doi: 10.1016/j.jtct.2021.09.009
   Google Scholar
• Limerick E, Fitzhugh C. Choice of donor source and conditioning regimen for hematopoietic stem cell transplantation in sickle cell disease. J Clin Med. 2019 Nov 15;8(11):1997.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Fuente J, Cappelli B, et al. The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Bone Marrow Transplant. 2020 Oct;55(10):1946–1954. doi: 10.1038/s41409-020-0847-z
   PubMed Web of Science ®Google Scholar
• Ngwube A, Shah N, Godder K, et al. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Adv. 2020 Aug 25;4(16):3894–3899. doi: 10.1182/bloodadvances.2020002236
   PubMed Web of Science ®Google Scholar
• Abraham A, Cluster A, Jacobsohn D, et al. Unrelated umbilical cord Blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial. Biol Blood Marrow Transplant. 2017 Sep;23(9):1587–1592. doi: 10.1016/j.bbmt.2017.05.027
   PubMed Web of Science ®Google Scholar
• Kanter J, Falcon C. Gene therapy for sickle cell disease: where we are now? Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):174–180.
   PubMedGoogle Scholar
• Esrick EB, Lehmann LE, Biffi A, et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med. 2021 Jan 21;384(3):205–215. doi: 10.1056/NEJMoa2029392
   PubMed Web of Science ®Google Scholar
• Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021 Jan 21;384(3):252–260. doi: 10.1056/NEJMoa2031054
   PubMed Web of Science ®Google Scholar
• Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med. 2022 Feb 17;386(7):617–628. doi: 10.1056/NEJMoa2117175
   PubMed Web of Science ®Google Scholar
• Frangoul H, Locatelli F, Bhatia M, et al. Efficacy and safety of a single dose of exagamglogene autotemcel for severe sickle cell disease. Blood. 2022;140(Supplement 1):29–31. doi: 10.1182/blood-2022-162353
   Google Scholar
• Malhotra M, Shenoy S. Umbilical cord blood as a hematopoietic stem cell source in transplantation for pediatric sickle cell disease: current challenges and strategies. Transfus Apher Sci. 2022 Oct;61(5):103554. doi: 10.1016/j.transci.2022.103554
   PubMed Web of Science ®Google Scholar
• Radhakrishnan K Reduced Toxicity Conditioning And Stem Cell Transplantation In Children With Sickle Cell Disease. Yale Medicine Thesis Digital Library: Yale University; 2013.
   Google Scholar
• Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003 Mar 15;101(6):2137–2143. doi: 10.1182/blood-2002-07-2090
   PubMed Web of Science ®Google Scholar
• Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013 Aug 8;122(6):1072–1078. doi: 10.1182/blood-2013-03-489112
   PubMed Web of Science ®Google Scholar
• Adamkiewicz TV, Szabolcs P, Haight A, et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant. 2007 Sep;11(6):641–644. doi: 10.1111/j.1399-3046.2007.00725.x
   PubMed Web of Science ®Google Scholar
• Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow transplant clinical trials network (BMT CTN). Biol Blood Marrow Transplant. 2012 Aug;18(8):1265–1272. doi: 10.1016/j.bbmt.2012.01.019
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Eapen M, Scaravadou A, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011 Sep;17(9):1375–1382. doi: 10.1016/j.bbmt.2011.01.012
   PubMed Web of Science ®Google Scholar
• Vander Lugt MT, Chen X, Escolar ML, et al. Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders. Blood Adv. 2020 Jul 14;4(13):3041–3052. doi: 10.1182/bloodadvances.2020001940
   PubMed Web of Science ®Google Scholar
• Parikh S, Brochstein JA, Galamidi E, et al. Allogeneic stem cell transplantation with omidubicel in sickle cell disease. Blood Adv. 2021 Feb 9;5(3):843–852. doi: 10.1182/bloodadvances.2020003248
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009 Dec 10;361(24):2309–2317. doi: 10.1056/NEJMoa0904971
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Wu CJ, Tisdale JF. In mixed hematopoietic chimerism, the donor red cells win. Haematologica. 2011 Jan;96(1):13–15. doi: 10.3324/haematol.2010.035576
   PubMed Web of Science ®Google Scholar
• Fitzhugh CD, Cordes S, Taylor T, et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood. 2017 Oct 26;130(17):1946–1948. doi: 10.1182/blood-2017-03-772392
   PubMed Web of Science ®Google Scholar
• Saraf SL, Oh AL, Patel PR, et al. Nonmyeloablative stem cell transplantation with alemtuzumab/Low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant. 2016 Mar;22(3):441–448. doi: 10.1016/j.bbmt.2015.08.036
   PubMed Web of Science ®Google Scholar
• Alzahrani M, Damlaj M, Essa M, et al. Outcome of age-adapted approach to HLA-Identical related hematopoietic stem cell transplantation in severe sickle cell disease: Saudi experience. Blood. 2018;132(Supplement 1):3468–3468. doi: 10.1182/blood-2018-99-115800
   Google Scholar
• Nickel RS, Chiang KY, Hardy SJ, et al. Nonmyeloablative HLA-Identical sibling donor transplantation for children and young adults with sickle cell disease: interim results of the SUN multicenter phase II trial. Blood. 2021 Nov 23;138:1799.
   Web of Science ®Google Scholar
• Ghannam JY, Xu X, Maric I, et al. Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. Blood. 2020 Apr 2;135(14):1185–1188. doi: 10.1182/blood.2019004001
   PubMed Web of Science ®Google Scholar
• Anurogo D, Yuli Prasetyo Budi N, Thi Ngo MH, et al. Cell and gene therapy for anemia: hematopoietic stem cells and gene Editing. Int J Mol Sci. 2021 Jun 10;22(12):6275. doi: 10.3390/ijms22126275
   PubMed Web of Science ®Google Scholar
• Goyal S, Tisdale J, Schmidt M, et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med. 2022 Jan 13;386(2):138–147. doi: 10.1056/NEJMoa2109167
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Fitzhugh CD, Tisdale JF. Incidence of second cancers after allogeneic hematopoietic stem cell transplantation using reduced-dose radiation. Blood. 2009 Jul 2;114(1):225. author reply 225-6. doi: 10.1182/blood-2009-03-209015
   PubMed Web of Science ®Google Scholar
• Darbari DS, Liljencrantz J, Ikechi A, et al. Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant. Br J Haematol. 2019 Feb;184(4):690–693. doi: 10.1111/bjh.15169
   PubMed Web of Science ®Google Scholar
• Leonard A, Furstenau D, Abraham A, et al. Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease. Blood Adv. 2023 Jan 24;7(2):227–234. doi: 10.1182/bloodadvances.2022008137
   PubMed Web of Science ®Google Scholar
• Woodard P, Helton KJ, Khan RB, et al. Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br J Haematol. 2005 May;129(4):550–552. doi: 10.1111/j.1365-2141.2005.05491.x
   PubMed Web of Science ®Google Scholar
• Mynarek M, Bettoni da Cunha Riehm C, Brinkmann F, et al. Normalized transcranial Doppler velocities, stroke prevention and improved pulmonary function after stem cell transplantation in children with sickle cell anemia. Klin Padiatr. 2013 May;225(3):127–132. doi: 10.1055/s-0033-1333754
   PubMed Web of Science ®Google Scholar
• Whitehead MT, Smitthimedhin A, Webb J, et al. Cerebral Blood flow and Marrow diffusion alterations in children with sickle cell anemia after bone Marrow transplantation and transfusion. AJNR Am J Neuroradiol. 2018 Nov;39(11):2132–2139. doi: 10.3174/ajnr.A5830
   PubMed Web of Science ®Google Scholar
• Bernaudin F, Verlhac S, Peffault de Latour R, et al. Association of matched sibling donor hematopoietic stem cell transplantation with transcranial Doppler velocities in children with sickle cell anemia. JAMA. 2019 Jan 22;321(3):266–276. doi: 10.1001/jama.2018.20059
   PubMed Web of Science ®Google Scholar
• King AA, McKinstry RC, Wu J, et al. Functional and radiologic assessment of the Brain after reduced-intensity unrelated donor transplantation for severe sickle cell disease: blood and Marrow transplant clinical trials network study 0601. Biol Blood Marrow Transplant. 2019 May;25(5):e174–e178. doi: 10.1016/j.bbmt.2019.01.008
   PubMed Web of Science ®Google Scholar
• Hulbert ML, Fields ME, Guilliams KP, et al. Normalization of cerebral hemodynamics after hematopoietic stem cell transplant in children with sickle cell disease. Blood. 2023 Jan 26;141(4):335–344. doi: 10.1182/blood.2022016618
   PubMed Web of Science ®Google Scholar
• Covi S, Ravindranath Y, Farooqi A, et al. Changes in bi-ventricular function after hematopoietic stem cell transplant as assessed by speckle tracking echocardiography. Pediatr Cardiol. 2018 Feb;39(2):365–374. doi: 10.1007/s00246-017-1764-9
   PubMed Web of Science ®Google Scholar
• Sachdev V, Hsieh M, Jeffries N, et al. Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease. Blood Adv. 2019 Oct 8;3(19):2816–2824. doi: 10.1182/bloodadvances.2019000387
   PubMed Web of Science ®Google Scholar
• Friedman D, Dozor AJ, Milner J, et al. Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. Bone Marrow Transplant. 2021 Sep;56(9):2221–2230. doi: 10.1038/s41409-021-01298-7
   PubMed Web of Science ®Google Scholar
• Ruhl AP, Shalhoub R, Jeffries N, et al. Pulmonary function before and after hematopoietic cell transplant in people living with sickle cell disease. Blood. 2022;140(Supplement 1):8294–8295. doi: 10.1182/blood-2022-157235
   Google Scholar
• Pedersen SJV, Monagel DA, Mammen C, et al. Stable renal function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2020 Sep;67(9):e28568. doi: 10.1002/pbc.28568
   PubMed Web of Science ®Google Scholar
• Limerick E, Saraf SL, Jeffries N, et al. Nonmyeloablative transplant for sickle cell disease does not lead to kidney dysfunction post-HSCT. Blood. 2021;138(Supplement 1):984–984. doi: 10.1182/blood-2021-153230
   Google Scholar
• Nickel RS, Seashore E, Lane PA, et al. Improved splenic function after hematopoietic stem cell transplant for sickle cell disease. Pediatr Blood Cancer. 2016 May;63(5):908–913. doi: 10.1002/pbc.25904
   PubMed Web of Science ®Google Scholar
• Brachet C, Heinrichs C, Tenoutasse S, et al. Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2007 Jul;29(7):445–450. doi: 10.1097/MPH.0b013e31806451ac
   PubMed Web of Science ®Google Scholar
• Lukusa AK, Vermylen C, Vanabelle B, et al. Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles. Pediatr Hematol Oncol. 2009 Jun;26(4):186–194. doi: 10.1080/07357900902892780
   PubMed Web of Science ®Google Scholar
• Zhao J, Beebe K, Magee K, et al. Adolescent male fertility following reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in non-malignant disorders. Pediatr Transplant. 2019 Sep;23(6):e13496. doi: 10.1111/petr.13496
   PubMed Web of Science ®Google Scholar
• Elchuri SV, Williamson Lewis R, Quarmyne MO, et al. Longitudinal Description of gonadal function in sickle-cell patients treated with hematopoietic stem cell transplant using Alkylator-based conditioning regimens. J Pediatr Hematol Oncol. 2020 Oct;42(7):e575–e582. doi: 10.1097/MPH.0000000000001782
   PubMed Web of Science ®Google Scholar
• George SA, Lai KW, Lewis RW, et al. Comparison of anti-Mullerian hormone levels pre- and post-hematopoietic cell transplantation in pediatric and adolescent females with sickle cell disease. Transplant Cell Ther. 2022 Nov;28(11):e770 1–e770 6. doi: 10.1016/j.jtct.2022.08.014
   Google Scholar
• Boga C, Asma S, Ozer C, et al. Gonadal status and sexual function at long-term follow-up after allogeneic stem cell transplantation in adult patients with sickle cell disease. Exp Clin Transplant. 2022 Mar 15; doi: 10.6002/ect.2021.0392
   Google Scholar
• Jones RJ, DeBaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood. 2021 Sep 16;138(11):942–947.
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Bonner M, Pierciey FJ, et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. 2020 May 12;4(9):2058–2063. doi: 10.1182/bloodadvances.2019001330
   PubMed Web of Science ®Google Scholar
• Lawal RA, Mukherjee D, Limerick EM, et al. Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism. Blood. 2022 Dec 8;140(23):2514–2518. doi: 10.1182/blood.2022017960
   PubMed Web of Science ®Google Scholar
• Eapen M, Brazauskas R, Williams DA, et al. Secondary neoplasms after hematopoietic cell transplant for sickle cell disease. J Clin Oncol. 2023 Apr 20;41(12):2227–2237. doi: 10.1200/JCO.22.01203
   PubMed Web of Science ®Google Scholar
• Cattoni A, Molinari S, Gaiero A, et al. Thyroid disorders following hematopoietic stem cell transplantation in childhood: impact of conditioning regimen on thyroid dysfunction, volume changes, and occurrence of nodules. Transplant Cell Ther. 2022 Aug;28(8):e506 1–e506 12. doi: 10.1016/j.jtct.2022.05.040
   Google Scholar
• Bruno B, Souillet G, Bertrand Y, et al. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant. 2004 Jul;34(2):143–147. doi: 10.1038/sj.bmt.1704549
   PubMed Web of Science ®Google Scholar
• Madden LM, Hayashi RJ, Chan KW, et al. Long-term follow-up after reduced-intensity conditioning and stem cell transplantation for childhood nonmalignant disorders. Biol Blood Marrow Transplant. 2016 Aug;22(8):1467–1472. doi: 10.1016/j.bbmt.2016.04.025
   PubMed Web of Science ®Google Scholar
• Ambrusko SJ, Gunawardena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer. 2006 Dec;47(7):907–913. doi: 10.1002/pbc.20791
   PubMed Web of Science ®Google Scholar
• Bernaudin F, Pondarre C, Galambrun C, et al. Allogeneic/Matched related transplantation for beta-thalassemia and sickle cell anemia. Adv Exp Med Biol. 2017;1013:89–122.
   PubMed Web of Science ®Google Scholar
• Alsaied T, Niss O, Tretter JT, et al. Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. Sci Rep. 2020 Feb 4;10(1):1767. doi: 10.1038/s41598-020-58662-8
   PubMed Web of Science ®Google Scholar
• Giordano P, Urbano F, Lassandro G, et al. Mechanisms of bone impairment in sickle bone disease. Int J Environ Res Public Health. 2021 Feb 13;18(4):1832. doi: 10.3390/ijerph18041832
   PubMed Web of Science ®Google Scholar
• Miller RG, Segal JB, Ashar BH, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol. 2006 Apr;81(4):236–241. doi: 10.1002/ajh.20541
   PubMed Web of Science ®Google Scholar
• Kendler DL, Body JJ, Brandi ML, et al. Bone management in hematologic stem cell transplant recipients. Osteoporos Int. 2018 Dec;29(12):2597–2610. doi: 10.1007/s00198-018-4669-4
   PubMed Web of Science ®Google Scholar
• Kendler DL, Body JJ, Brandi ML, et al. Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. J Bone Oncol. 2021 Jun;28:100361.
   PubMed Web of Science ®Google Scholar
• Elchuri SV, Williamson RS, Clark Brown R, et al. The effects of hydroxyurea and bone marrow transplant on anti-Mullerian hormone (AMH) levels in females with sickle cell anemia. Blood Cells Mol Dis. 2015 Jun;55(1):56–61. doi: 10.1016/j.bcmd.2015.03.012
   PubMed Web of Science ®Google Scholar
• Nickel RS, Maher JY, Hsieh MH, et al. Fertility after curative therapy for sickle cell disease: a comprehensive review to Guide care. J Clin Med. 2022 Apr 21;11(9):2318. doi: 10.3390/jcm11092318
   PubMed Web of Science ®Google Scholar
• Matthews M, Pollack R. Acute pain crisis in a patient with sickle cell disease undergoing ovarian simulation for fertility preservation prior to curative stem cell transplantation: case report and literature review. J Assist Reprod Genet. 2017 Nov;34(11):1445–1448. doi: 10.1007/s10815-017-1008-1
   PubMed Web of Science ®Google Scholar
• Demeestere I, Simon P, Dedeken L, et al. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod. 2015 Sep;30(9):2107–2109. doi: 10.1093/humrep/dev128
   PubMed Web of Science ®Google Scholar
• Pecker LH, Maher JY, Law JY, et al. Risks associated with fertility preservation for women with sickle cell anemia. Fertil Steril. 2018 Sep;110(4):720–731. doi: 10.1016/j.fertnstert.2018.05.016
   PubMed Web of Science ®Google Scholar
• Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997 Mar 27;336(13):897–904. doi: 10.1056/NEJM199703273361301
   PubMed Web of Science ®Google Scholar
• Baker KS, Leisenring WM, Goodman PJ, et al. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood. 2019 Jun 27;133(26):2790–2799. doi: 10.1182/blood.2018874115
   PubMed Web of Science ®Google Scholar
• Leonard A, Tisdale JF. A pause in gene therapy: reflecting on the unique challenges of sickle cell disease. Mol Ther. 2021 Apr 7;29(4):1355–1356.
   PubMedGoogle Scholar
• Mouhieddine TH, Sperling AS, Redd R, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 Jun 12;11(1):2996. doi: 10.1038/s41467-020-16805-5
   PubMed Web of Science ®Google Scholar
• Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for Lymphoma. J Clin Oncol. 2017 May 10;35(14):1598–1605. doi: 10.1200/JCO.2016.71.6712
   PubMed Web of Science ®Google Scholar